News & Updates

Targeted oral naltrexone results in a significant reduction in drinking outcomes among sexual and gender minority men (SGM) with mild to moderate alcohol use disorder (AUD) during treatment, reports a study. This beneficial effect persists up to 6 months post-treatment.

In individuals with Wilson disease (WD), a rare disease of copper metabolism, ALXN1840 led to significantly greater copper mobilization compared with standard of care (SoC), findings from a rater-blinded phase III study have shown.

In a cohort of middle-aged individuals from South Korea, the initial weight loss at 4 years appears to contribute to an increased risk of major adverse cardiovascular events (MACEs), which may be explained by residual cardiovascular burden, according to a study. However, the risk increase disappears among individuals with sustained weight loss ≥ 6 years.